Chairs: Kalil Abdullah, MD, and Shawn Hervey-Jumper, MD
CNS 2024 Meeting Highlights
The 2024 CNS Annual Meeting will be held in Houston, Texas, on September 28 – October 2, 2024. The scientific program of the Tumor Section will feature the following themes: (1) Evolution of surgical management of brain cancers in the age of targeted molecular therapies and (2) Intraoperative visualization and adjunctive therapy during brain tumor resection. Award-winning abstracts will follow Monday’s Scientific Session.
Since initial clinical approvals in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents’ therapeutic monoclonal antibodies acting as signal transduction inhibitors has been the backbone of precision medicine for cancer treatment. Only recently have these strategies demonstrated benefits for patients with brain cancer. Monday, September 20, 2024 (Scientific Session I) will feature internationally recognized speakers addressing this emerging topic. Didactic and case discussions will include (1) “The role of IDH inhibitors in the management of diffuse low and high-grade gliomas”, (2) the “Evolution of targeted therapies for skull base tumors” and (3) “Surgical management of spine metastasis – when to consider targeted molecular therapies.” Our list of speakers will include Daniel Cahill, MD, PhD, from Massachusetts General Hospital; Analiz Rodriguez, MD, PhD, from the University of Arkansas Medical Center and W. Christopher Newman, MD, from Memorial Sloan Kettering Cancer Center.
Tuesday, October 1, 2024, (Session II) will focus on Focus Ultrasound and intraoperative photodynamic therapy during brain tumor resection. This session will offer a fresh perspective on technologies delivered in the intraoperative setting to optimize tumor visualization and the delivery of cancer-directed therapies. Didactic and case discussions will include “Photodynamic Therapy for Malignant Glioma,” “Focus Ultrasound for Gliomas” and “Use of Focused Ultrasound for Treatment of Brain Metastases”. Tuesday’s speakers will include Nicolas Reyns, MD, PhD, from the University Hospital of Lille and Nir Lipsman MD, PhD, from the University of Toronto.